Avalyn Pharma Inc. Common Stock(AVLN)

Biotechnology · Boston, MA

$25.66-1.37 (-5.07%)

Delayed quote: Oct 6, 2026, 1:59 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T18:00:59.084Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:00:59.084Z.

Quote observation: 2026-10-06T17:59:50.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,137,587,218
TTM revenue · period ending 2026-06-30: N/A

FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

AVLN PS Ratio Metrics

PS RATIO

N/A

AVLN Competitors' PS Ratio

AVLN

Avalyn Pharma Inc. Common Stock

Current

Market Cap

$1.14B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GDRX

GoodRx Holdings, Inc.

vs AVLN

Market Cap

$1.14B

PS Ratio

1.45

TTM Avg

1.25

3Y Avg

2.39

5Y Avg

4.44

AMPH

Amphastar Pharmaceuticals, Inc.

vs AVLN

Market Cap

$1.14B

PS Ratio

1.56

TTM Avg

1.49

3Y Avg

2.58

5Y Avg

3.06

HROW

Harrow Health, Inc.

vs AVLN

Market Cap

$1.13B

PS Ratio

4.11

TTM Avg

5.90

3Y Avg

5.82

5Y Avg

5.19

NKTR

Nektar Therapeutics

vs AVLN

Market Cap

$1.15B

PS Ratio

20.98

TTM Avg

23.60

3Y Avg

9.65

5Y Avg

9.36

DMRA

Damora Therapeutics, Inc.

vs AVLN

Market Cap

$1.16B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

REPL

Replimune Group, Inc.

vs AVLN

Market Cap

$1.11B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TNDM

Tandem Diabetes Care, Inc.

vs AVLN

Market Cap

$1.11B

PS Ratio

1.07

TTM Avg

1.26

3Y Avg

1.88

5Y Avg

3.56

OPK

OPKO Health, Inc.

vs AVLN

Market Cap

$1.11B

PS Ratio

1.88

TTM Avg

1.68

3Y Avg

1.45

5Y Avg

1.34

STAA

STAAR Surgical Company

vs AVLN

Market Cap

$1.11B

PS Ratio

3.26

TTM Avg

4.68

3Y Avg

4.75

5Y Avg

8.45

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Avalyn Pharma Inc. Common Stock (AVLN)	$1.14B	N/A	N/A	N/A	N/A
GoodRx Holdings, Inc. (GDRX)vs ›	$1.14B	1.45	1.25	2.39	4.44
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.14B	1.56	1.49	2.58	3.06
Harrow Health, Inc. (HROW)vs ›	$1.13B	4.11	5.90	5.82	5.19
Nektar Therapeutics (NKTR)vs ›	$1.15B	20.98	23.60	9.65	9.36
Damora Therapeutics, Inc. (DMRA)vs ›	$1.16B	N/A	N/A	N/A	N/A
Replimune Group, Inc. (REPL)vs ›	$1.11B	N/A	N/A	N/A	N/A
Tandem Diabetes Care, Inc. (TNDM)vs ›	$1.11B	1.07	1.26	1.88	3.56
OPKO Health, Inc. (OPK)vs ›	$1.11B	1.88	1.68	1.45	1.34
STAAR Surgical Company (STAA)vs ›	$1.11B	3.26	4.68	4.75	8.45

How this was calculated

The four-quarter calculation detail is unavailable for this stored observation.

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

AVLN PS Ratio Metrics

AVLN Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics